Pliant Therapeutics, Inc.: Focused on treatments for fibrotic diseases by harnessing the therapeutic potential of integrin biology and TGF-β modulation. Lead program is a small molecule dual selective inhibitor of avb6/avb1 integrins for IPF, primary sclerosing cholangitis (PSC), and renal fibrosis - received orphan drug designation and will enter Ph1 in December 2018. Second program is a selective avb1 inhibitor for the treatment of end stage liver fibrosis and has entered into development candidate selection.
Website:
Address:
260 Littlefield Avenue
South San Francisco, CA 94080
USA

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.